[Form 3] FATE THERAPEUTICS INC Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Fate Therapeutics (FATE) filed a Form 3, the initial statement of beneficial ownership for its Chief Financial Officer under Section 16. The filing states that no securities are beneficially owned by the reporting person as of the event date 10/20/2025. The form was filed by one reporting person, with a Power of Attorney on file (Exhibit 24) and signed by Cindy Tahl, as Attorney-in-Fact on 10/21/2025.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Adawi Kamal

(Last) (First) (Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO CA 92131

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/20/2025

3. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Cindy Tahl, as Attorney-in-Fact	10/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Fate Therapeutics (FATE) file?

A Form 3, the initial statement of beneficial ownership under Section 16.

Whose ownership does the Form 3 cover at FATE?

The company's Chief Financial Officer (officer status indicated in the filing).

What holdings were reported in the Form 3 for FATE?

The filing states no securities are beneficially owned.

What is the event date in the FATE Form 3?

The event date is 10/20/2025.

Was the FATE Form 3 a joint filing?

No. It was filed by one reporting person.

Who signed the FATE Form 3?

It was signed by /s/ Cindy Tahl, as Attorney-in-Fact on 10/21/2025.

Does the FATE Form 3 include a Power of Attorney?

Yes. The remarks reference Exhibit 24 - Power of Attorney.